| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/03602538409029964 |
| P698 | PubMed publication ID | 6543526 |
| P2093 | author name string | Tognoni G | |
| Young JF | |||
| Latini R | |||
| Bonati M | |||
| Garattini S | |||
| P433 | issue | 7 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 1355-1383 | |
| P577 | publication date | 1984-01-01 | |
| P1433 | published in | Drug Metabolism Reviews | Q5308857 |
| P1476 | title | Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat, and mouse | |
| P478 | volume | 15 |
| Q42608770 | Acute high-caffeine exposure increases autophagic flux and reduces protein synthesis in C2C12 skeletal myotubes |
| Q33774756 | Allometric issues in drug development |
| Q46829244 | Allometric principles for interspecies extrapolation in toxicological risk assessment--empirical investigations |
| Q28751304 | Allometric scaling of xenobiotic clearance: uncertainty versus universality |
| Q33933548 | Alteration of the behavioral effects of nicotine by chronic caffeine exposure. |
| Q28710144 | Animal models and conserved processes |
| Q30559468 | Are we dependent upon coffee and caffeine? A review on human and animal data |
| Q57420068 | CAFFEINATED BEVERAGES AND DECREASED FERTILITY |
| Q51023401 | Caffeine administration modulates TGF-β signaling but does not attenuate blunted alveolarization in a hyperoxia-based mouse model of bronchopulmonary dysplasia. |
| Q41460169 | Caffeine and paraxanthine pharmacokinetics in the rabbit: concentration and product inhibition effects |
| Q72579783 | Caffeine augmentation of electroconvulsive seizures |
| Q43502870 | Caffeine augments proteinuria in puromycin-aminonucleoside nephrotic rats |
| Q36626809 | Caffeine increases psychomotor performance on the effort expenditure for rewards task |
| Q35803244 | Caffeine prevents acute mortality after TBI in rats without increased morbidity |
| Q37617084 | Caffeine protects against experimental acute pancreatitis by inhibition of inositol 1,4,5-trisphosphate receptor-mediated Ca2+ release |
| Q33916981 | Clinically significant pharmacokinetic interactions between dietary caffeine and medications |
| Q52235333 | Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: mean allometric coefficient of 0.66. |
| Q35074368 | Cytochrome P450-dependent metabolism of caffeine in Drosophila melanogaster |
| Q51903122 | Disposition Kinetics of Caffeine and Paraxanthine in Nile Tilapia (Oreochromis niloticus): Characterization of the Main Metabolites |
| Q46886661 | Effects of amphetamine, diazepam and caffeine on polysomnography (EEG, EMG, EOG)-derived variables measured using telemetry in Cynomolgus monkeys |
| Q36718931 | Effects of bladder resorption on pharmacokinetic data analysis. |
| Q70261458 | Gas chromatographic-mass spectrometric quantitation of tri-, di- and monomethylxanthines and uric acids from hepatocyte incubation media |
| Q67868774 | High-performance liquid chromatographic separation of caffeine, theophylline, theobromine and paraxanthine in rat brain and serum |
| Q71850705 | Induction of liver and kidney CYP1A1/1A2 by caffeine in rat |
| Q36859972 | Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs |
| Q68782751 | Interspecies extrapolation of pharmacokinetics |
| Q37763075 | Interspecies scaling for the prediction of drug clearance in children: application of maximum lifespan potential and an empirical correction factor |
| Q24604052 | Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease |
| Q69393411 | Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure |
| Q41109384 | Physiologically-based modelling in mice suggests an aggravated loss of clearance capacity after toxic liver damage |
| Q64083777 | Physiology and effects of nucleosides in mice lacking all four adenosine receptors |
| Q51898567 | Predicting oral clearance in humans: how close can we get with allometry? |
| Q33605312 | Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations |
| Q46803858 | Reprint of "Effects of amphetamine, diazepam and caffeine on polysomnography (EEG, EMG, EOG)-derived variables measured using telemetry in Cynomolgus monkeys". |
| Q34635619 | Scaling basic toxicokinetic parameters from rat to man. |
| Q34659193 | Species differences in pharmacokinetics and drug teratogenesis |
| Q74603803 | Strain differences in CYP3A-mediated C-8 hydroxylation (1,3,7-trimethyluric acid formation) of caffeine in Wistar and Dark Agouti rats. Rapid metabolism of caffeine in debrisoquine poor metabolizer model rats |
| Q30884017 | The Prediction of Methylmercury Elimination Half-Life in Humans using Animal Data: A Neural Network/Rough Sets Analysis |
| Q38155807 | The buzz on caffeine in invertebrates: effects on behavior and molecular mechanisms. |
| Q44614582 | The effects of obesity and exercise on the pharmacokinetics of caffeine in lean and obese volunteers |
| Q36697929 | The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects |
| Q48283521 | The pharmacokinetic principles behind scaling from preclinical results to phase I protocols |
| Q73197234 | The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans |
| Q43633471 | Uncertainty factors for chemical risk assessment: interspecies differences in the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates |
| Q40319987 | Use of PMA1 as a housekeeping biomarker for assessment of toxicant-induced stress in Saccharomyces cerevisiae |
Search more.